Selective hydroxamate based MMP inhibitors
US8232427B2 · kind B2 · utility
0Cited by
2References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 27, 2007 |
| Grant date | Jul 31, 2012 |
| Priority date | — |
| Expiry date | Mar 17, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/09
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a compound of formula (I):said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-9, and/or MMP-12 and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.